Low Dose Atrial Natriuretic Factor in Primary Aldosteronism: Renal, Hemodynamic, and Vascular Effects

Whether atrial natriuretic factor (ANT) plays a physiological role in primary aldosteronism has yet to be determined. In the present study, the renal, hemodynamic, humoral, and vascular effects of a synthetic (WY- 47663) human analogue were studied in five water-loaded (15 ml H2O/kg) patients with adenomatous primary aldosteronism, a salt-sensitive, low renin, volumeexpanded syndrome. ANF was infused for 3 hours at a low rate (0.005 μg/kg/min), which approximately doubled circulating immunoreactive ANF. Glomerular filtration rate and renal blood flow (inulin and para-aminohippurate clearance) remained stable, but sodium excretion increased significantly suggesting a dissociation between renal hemodynamics and natriuresis as well as a direct inhibitory effect on tubular sodium reabsorption by ANF. Intra-arterial diastolic blood pressure, heart rate, forearm blood flow (plethysmographic method), and arterial plasma norepinephrine did not change, but systolic blood pressure declined and hematocrit rose suggesting plasma volume contraction by ANF. Plasma aldosterone levels were unchanged indicating a loss of ANF-mediated aldosterone inhibition, possibly related to qualitative or quantitative alterations of ANF receptors in tumoral adrenal tissue. Infusion of the analogue into the brachial artery was at a rate of 0.005 μg/dl forearm tissue/min×30 minutes, which also doubled local immunoreactive venous ANF concentrations and vasodilated forearm arterioles. These data suggest a physiological role for ANF in modulating body fluid volume even in human primary aldosteronism.

[1]  R. Pedrinelli,et al.  Dietary Sodium Change in Primary Aldosteronism Atrial Natriuretic Factor, Hormonal, and Vascular Responses , 1988, Hypertension.

[2]  A. Richards,et al.  Low dose infusions of 26- and 28-amino acid human atrial natriuretic peptides in normal man. , 1988, The Journal of clinical endocrinology and metabolism.

[3]  P. Erne,et al.  Greater vasodilator responsiveness to atrial natriuretic peptide in low-renin essential hypertensives. , 1987, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[4]  J. Biollaz,et al.  Site of the action of a synthetic atrial natriuretic peptide evaluated in humans. , 1987, Kidney international.

[5]  H. Vanderstichele,et al.  Influence of a prolonged tamoxifen administration on steroidogenesis by incubated rat testes. , 1987, Journal of steroid biochemistry.

[6]  K. Kangawa,et al.  Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man. , 1987, The Journal of clinical investigation.

[7]  H. Sekihara,et al.  Plasma Levels of Atrial Natriuretic Peptide in Primary Aldosteronism and Essential Hypertension , 1987 .

[8]  A. Shore,et al.  Changes in the plasma levels of atrial natriuretic peptides during mineralocorticoid escape in man. , 1987, Clinical science.

[9]  J. Granger,et al.  Elevated levels of atrial natriuretic peptide during aldosterone escape. , 1987, The American journal of physiology.

[10]  S. Atlas,et al.  Effects of atrial natriuretic factor on the kidney and the renin-angiotensin-aldosterone system. , 1987, Endocrinology and metabolism clinics of North America.

[11]  S. Bloom,et al.  Atrial natriuretic peptide: evidence of action as a natriuretic hormone at physiological plasma concentrations in man. , 1987, Clinical science.

[12]  M. Boscaro,et al.  Effect of alpha-human atrial natriuretic peptide in low renin essential hypertension and primary aldosteronism. , 1987, Clinical and experimental hypertension. Part A, Theory and practice.

[13]  P. Erne,et al.  The vasodilator potency of atrial natriuretic peptide in man. , 1987, Circulation.

[14]  M. Fiksen-Olsen,et al.  Renal effects of ANP without changes in glomerular filtration rate and blood pressure. , 1986, The American journal of physiology.

[15]  J. Seidman,et al.  Atrial natriuretic peptide transcription, secretion, and glomerular receptor activity during mineralocorticoid escape in the rat. , 1986, The Journal of clinical investigation.

[16]  R. Pedrinelli,et al.  Vascular responses to ouabain and norepinephrine in low and normal renin hypertension. , 1986, Hypertension.

[17]  H. Nawata,et al.  Lack of inhibitory effect of alpha-human atrial natriuretic polypeptide on aldosteronogenesis in aldosterone-producing adenoma. , 1986, The Journal of clinical endocrinology and metabolism.

[18]  D. Wilson,et al.  Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. , 1986, The American journal of physiology.

[19]  J. Biollaz,et al.  Four‐Hour Infusions of Synthetic Atrial Natriuretic Peptide in Normal Volunteers , 1986, Hypertension.

[20]  E. Espiner,et al.  Atrial Natriuretic Peptide in Humans: Production and Clearance by Various Tissues , 1986, Hypertension.

[21]  P. Needleman,et al.  Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood-pressure homeostasis. , 1986, The New England journal of medicine.

[22]  T. Tunny,et al.  PLASMA ATRIAL NATRIURETIC PEPTIDE IN PRIMARY ALDOSTERONISM (BEFORE AND AFTER TREATMENT) AND IN BARTTER'S AND GORDON'S SYNDROMES , 1986, The Lancet.

[23]  A. Folsom,et al.  Serum calcium fractions in essential hypertensive and matched normotensive subjects. , 1986, Hypertension.

[24]  N. Seidah,et al.  Structure-activity relationships of atrial natriuretic factor (ANF). III. Correlation of receptor affinity with relative potency on aldosterone production in zona glomerulosa cells. , 1985, Biochemical and biophysical research communications.

[25]  J. Laragh,et al.  Atrial natriuretic factor: structure and functional properties. , 1985, Kidney international.

[26]  T. Yukimura,et al.  Renal effects of a sythetic α-human atrial natriuretic polypeptide (α-hANP) in anesthetized dogs , 1984 .

[27]  T. Yukimura,et al.  Renal effects of a synthetic alpha-human atrial natriuretic polypeptide (alpha-hANP) in anesthetized dogs. , 1984, European journal of pharmacology.

[28]  D. E. DiRico,et al.  Plasma catecholamines in hypertension and pheochromocytoma determined using ion-pair reversed-phase chromatography with amperometric detection: investigation of the separation mechanism and clinical methodology. , 1981, Journal of chromatography.

[29]  E. Schnurr,et al.  Measurement of renal clearance of inulin and PAH in the steady state without urine collection. , 1980, Clinical nephrology.

[30]  J. Brown,et al.  Clinical, biochemical and pathological features of low-renin ("primary") hyperaldosteronism. , 1978, American heart journal.

[31]  R. Pedrinelli,et al.  The relationship of plasma and urinary aldosterone with sodium balance, plasma renin activity and age in normal subjects. , 1977, The Journal of nuclear medicine and allied sciences.

[32]  G. Zucchelli,et al.  Evaluation and comparison of four methods for plasma cortisol assay. , 1976, The Journal of nuclear biology and medicine.

[33]  D. Giannessi,et al.  Radioimmunoassay of aldosterone in crude plasma extracts. , 1976, The Journal of nuclear biology and medicine.

[34]  A. Salvetti,et al.  Measurement of plasma renin activity by angiotensin I radioimmunoassay: (I) an assessment of some methodological aspects. , 1972, The Journal of nuclear biology and medicine.

[35]  R. J. Whitney,et al.  The measurement of volume changes in human limbs , 1953, The Journal of physiology.